The TNFR1 antagonist Atrosimab reduces neuronal loss, glial activation and memory deficits in an acute mouse model of neurodegeneration
Abstract Tumor necrosis factor alpha (TNF-α) and its key role in modulating immune responses has been widely recognized as a therapeutic target for inflammatory and neurodegenerative diseases. Even though inhibition of TNF-α is beneficial for the treatment of certain inflammatory diseases, total neu...
Main Authors: | Natalia Ortí-Casañ, Ate S. Boerema, Karina Köpke, Amber Ebskamp, Jan Keijser, Yuequ Zhang, Tingting Chen, Amalia M. Dolga, Kerensa Broersen, Roman Fischer, Klaus Pfizenmaier, Roland E. Kontermann, Ulrich L. M. Eisel |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-06-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-36846-2 |
Similar Items
-
The TNFR1 Antagonist Atrosimab Is Therapeutic in Mouse Models of Acute and Chronic Inflammation
by: Fabian Richter, et al.
Published: (2021-07-01) -
Sequential treatment with a TNFR2 agonist and a TNFR1 antagonist improves outcomes in a humanized mouse model for MS
by: Valentina Pegoretti, et al.
Published: (2023-05-01) -
Co-modulation of TNFR1 and TNFR2 in an animal model of multiple sclerosis
by: Timon Fiedler, et al.
Published: (2023-04-01) -
Lipocalin 2 contributes to brain iron dysregulation but does not affect cognition, plaque load, and glial activation in the J20 Alzheimer mouse model
by: Doortje W. Dekens, et al.
Published: (2018-11-01) -
Targeting TNFR2 as a Novel Therapeutic Strategy for Alzheimer’s Disease
by: Natalia Ortí-Casañ, et al.
Published: (2019-02-01)